Literature DB >> 24687070

Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.

Daniel M Hartung, Deborah A Zarin, Jeanne-Marie Guise, Marian McDonagh, Robin Paynter, Mark Helfand.   

Abstract

BACKGROUND: ClinicalTrials.gov requires reporting of result summaries for many drug and device trials.
PURPOSE: To evaluate the consistency of reporting of trials that are registered in the ClinicalTrials.gov results database and published in the literature. DATA SOURCES: ClinicalTrials.gov results database and matched publications identified through ClinicalTrials.gov and a manual search of 2 electronic databases. STUDY SELECTION: 10% random sample of phase 3 or 4 trials with results in the ClinicalTrials.gov results database, completed before 1 January 2009, with 2 or more groups. DATA EXTRACTION: One reviewer extracted data about trial design and results from the results database and matching publications. A subsample was independently verified. DATA SYNTHESIS: Of 110 trials with results, most were industry-sponsored, parallel-design drug studies. The most common inconsistency was the number of secondary outcome measures reported (80%). Sixteen trials (15%) reported the primary outcome description inconsistently, and 22 (20%) reported the primary outcome value inconsistently. Thirty-eight trials inconsistently reported the number of individuals with a serious adverse event (SAE); of these, 33 (87%) reported more SAEs in ClinicalTrials.gov. Among the 84 trials that reported SAEs in ClinicalTrials.gov, 11 publications did not mention SAEs, 5 reported them as zero or not occurring, and 21 reported a different number of SAEs. Among 29 trials that reported deaths in ClinicalTrials.gov, 28% differed from the matched publication. LIMITATION: Small sample that included earliest results posted to the database.
CONCLUSION: Reporting discrepancies between the ClinicalTrials.gov results database and matching publications are common. Which source contains the more accurate account of results is unclear, although ClinicalTrials.gov may provide a more comprehensive description of adverse events than the publication. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Year:  2014        PMID: 24687070      PMCID: PMC4617780          DOI: 10.7326/M13-0480

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.

Authors:  An-Wen Chan; Asbjørn Hróbjartsson; Mette T Haahr; Peter C Gøtzsche; Douglas G Altman
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

2.  Medicine. Moving toward transparency of clinical trials.

Authors:  Deborah A Zarin; Tony Tse
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

3.  Adverse events in randomized trials: neglected, restricted, distorted, and silenced.

Authors:  John P A Ioannidis
Journal:  Arch Intern Med       Date:  2009-10-26

Review 4.  Dissemination and publication of research findings: an updated review of related biases.

Authors:  F Song; S Parekh; L Hooper; Y K Loke; J Ryder; A J Sutton; C Hing; C S Kwok; C Pang; I Harvey
Journal:  Health Technol Assess       Date:  2010-02       Impact factor: 4.014

Review 5.  A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.

Authors:  Eugene J Carragee; Eric L Hurwitz; Bradley K Weiner
Journal:  Spine J       Date:  2011-06       Impact factor: 4.166

6.  Ushering in a new era of open science through data sharing: the wall must come down.

Authors:  Joseph S Ross; Harlan M Krumholz
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

7.  The ClinicalTrials.gov results database--update and key issues.

Authors:  Deborah A Zarin; Tony Tse; Rebecca J Williams; Robert M Califf; Nicholas C Ide
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

8.  A model for dissemination and independent analysis of industry data.

Authors:  Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

Review 9.  Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.

Authors:  Rongwei Fu; Shelley Selph; Marian McDonagh; Kimberly Peterson; Arpita Tiwari; Roger Chou; Mark Helfand
Journal:  Ann Intern Med       Date:  2013-06-18       Impact factor: 25.391

10.  Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy.

Authors:  Mirjana Huić; Matko Marušić; Ana Marušić
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

View more
  69 in total

Review 1.  From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Authors:  Kanwal Pratap Singh Raghav; Sminil Mahajan; James C Yao; Brian P Hobbs; Donald A Berry; Rebecca D Pentz; Alda Tam; Waun K Hong; Lee M Ellis; James Abbruzzese; Michael J Overman
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

2.  Current landscape of type 1 diabetes mellitus-related interventional clinical trials registered on ClinicalTrials.gov: a cross-sectional study.

Authors:  Ruiming Liang; Jianyan Long; Qiuyi Zheng; Gang Yuan; Xinwen Chen; Ziyi Xin; Fenghua Lai; Yihao Liu
Journal:  Acta Diabetol       Date:  2021-02-05       Impact factor: 4.280

3.  Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.

Authors:  Lin Wang; Benjamin Rouse; Arielle Marks-Anglin; Rui Duan; Qiyuan Shi; Kevin Quach; Yong Chen; Christopher Cameron; Christopher H Schmid; Tianjing Li
Journal:  J Clin Epidemiol       Date:  2019-06-18       Impact factor: 6.437

4.  Evaluation of Journal Registration Policies and Prospective Registration of Randomized Clinical Trials of Nonregulated Health Care Interventions.

Authors:  Marleine Azar; Kira E Riehm; Nazanin Saadat; Tatiana Sanchez; Matthew Chiovitti; Lin Qi; Danielle B Rice; Brooke Levis; Claire Fedoruk; Alexander W Levis; Lorie A Kloda; Jonathan Kimmelman; Andrea Benedetti; Brett D Thombs
Journal:  JAMA Intern Med       Date:  2019-05-01       Impact factor: 21.873

Review 5.  Prevention of selective outcome reporting: let us start from the beginning.

Authors:  Rafael Dal-Ré; Ana Marušić
Journal:  Eur J Clin Pharmacol       Date:  2016-08-02       Impact factor: 2.953

6.  Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.

Authors:  Richeek Pradhan; Sonal Singh
Journal:  Drug Saf       Date:  2018-09       Impact factor: 5.606

7.  Is it time for computable evidence synthesis?

Authors:  Adam G Dunn; Florence T Bourgeois
Journal:  J Am Med Inform Assoc       Date:  2020-06-01       Impact factor: 4.497

Review 8.  Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-11       Impact factor: 3.455

9.  ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.

Authors:  Lisa M Schwartz; Steven Woloshin; Eugene Zheng; Tony Tse; Deborah A Zarin
Journal:  Ann Intern Med       Date:  2016-06-14       Impact factor: 25.391

10.  Automatic extraction of quantitative data from ClinicalTrials.gov to conduct meta-analyses.

Authors:  Richeek Pradhan; David C Hoaglin; Matthew Cornell; Weisong Liu; Victoria Wang; Hong Yu
Journal:  J Clin Epidemiol       Date:  2018-09-23       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.